Sponsor Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia.

Your donation will directly support this research project led by Dr. Aksinija A Kogan at Johns Hopkins Kimmel Cancer Center.

Support This Research

Support this research directly through verified donation platforms:

Donate via Johns Donate via LLS

Direct Support: All donations are processed securely through verified donation portals. When donating through the institution, specify that your gift supports leukemia research. LLS funds support leukemia research programs nationwide. 100% of your contribution advances leukemia research.

About This Project

DNA methyltransferase inhibitors (DNMTis) reexpress hypermethylated genes in cancers and leukemias and also activate endogenous retroviruses (ERVs), leading to interferon (IFN) signaling, in a process known as viral mimicry. In the present study we show that in the subset of acute myeloid leukemias (AMLs) with mutations in TP53, associated with poor prognosis, DNMTis, important drugs for treatment of AML, enable expression of ERVs and IFN and inflammasome signaling in a STING-dependent manner. We previously reported that in solid tumors poly ADP ribose polymerase inhibitors (PARPis) combined with DNMTis to induce an IFN/inflammasome response that is dependent on STING1 and is mechanistically linked to generation of a homologous recombination defect (HRD). We now show that STING1 activity is actually increased in TP53 mutant compared with wild-type (WT) TP53 AML. Moreover, in TP53 mutant AML, STING1-dependent IFN/inflammatory signaling is increased by DNMTi treatment, whereas in AMLs wi...

Your Impact

By sponsoring this research project, you're directly contributing to advancing leukemia treatment and finding cures. Every dollar helps researchers conduct critical studies, purchase equipment, and support clinical trials that can save lives.

Back to Project Details